TRANSCODE THERAPEUTICS, INC. Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) of -$3.07 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-23.
Discontinued › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2021-08-23
- TRANSCODE THERAPEUTICS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2021-06-30 was -$3.07M.
- TRANSCODE THERAPEUTICS, INC. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2021-03-31 was $3.94M.
| Period end | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month |
|---|---|---|
| 2021-06-30 | -$3.07M 10-Q · filed 2021-08-23 | $867.00K 10-Q · filed 2021-08-23 |
| 2021-03-31 | $3.94M 10-Q · filed 2021-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |